Morgan Stanley Alx Oncology Holdings Inc Call Options Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding ALXO
# of Institutions
91Shares Held
35.1MCall Options Held
34KPut Options Held
36.9K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$4.27 Million6.44% of portfolio
-
Redmile Group, LLC San Francisco, CA3.64MShares$1.6 Million0.24% of portfolio
-
Tang Capital Management LLC San Diego, CA3.16MShares$1.39 Million0.13% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$1.18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.84MShares$808,6860.0% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $17.9M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...